A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

Bimiralisib is an orally bioavailable pan-phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the response rate to bimiralisib at 2 continuous dose levels (60 mg and 80 mg) in patie...

Full description

Bibliographic Details
Main Authors: Graham P. Collins, Toby A. Eyre, Debora Schmitz-Rohmer, William Townsend, Rakesh Popat, Lisa Giulino-Roth, Paul A. Fields, Fatime Krasniqi, Carole Soussain, Anastasios Stathis, Nebojsa Andjelkovic, David Cunningham, Danijela Mandic, Sinisa Radulovic, Ivan Tijanic, Netanel A. Horowitz, Sabira Kurtovic, Elisabeth Schorb, Christian Schmidt, Saša Dimitrijević, Martin Dreyling
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000656

Internet

http://journals.lww.com/10.1097/HS9.0000000000000656

Similar Items